3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Ifosfamide
6
Leucovorin
5
Doxorubicin
4
Dexrazoxane
4
Cisplatin
4
Methotrexate
3
Filgrastim
3
Carboplatin
3
mifamurtide
2
glucarpidase
2
Radiotherapy
2
Neoadjuvant Therapy
2
Mesna
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cryosurgery
2
Chemotherapy, Adjuvant
2
temsirolimus
1
sintilimab
1
sargramostim
1
saracatinib
1
samarium Sm-153 lexidronam
1
robatumumab
1
pembrolizumab
1
pegfilgrastim
1
pazopanib
1
omburtamab I-131
1
niraparib
1
lexatumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Osteosarcoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts